Incidence of therapy-related acute leukaemia in mitoxantrone-treated multiple sclerosis patients in Germany

Therapeutic Advances in Neurological Disorders

Volumn 5, Issue 2, 2012, Pages 75-79

  Stroet, Anke ^a   Hemmelmann, Claudia ^a   Starck, Michaela ^a   Zettl, Uwe ^a   Dörr, Jan ^a   Paul, Friedemann ^a   Flachenecker, Peter ^a   Fleischer, Vinzenz ^a   Zipp, Frauke ^a   Nackel, Holger ^a   Kieseier, Bernd C ^a   Ziegler, Andreas ^a   Gold, Ralf ^a   Chan, Andrew ^a  

^a ST JOSEF HOSPITAL   (Germany)

Author keywords

escalation therapy; leukaemia; mitoxantrone; multiple sclerosis; risk profile

Indexed keywords

AZATHIOPRINE; GLUCOCORTICOID; MITOXANTRONE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; BONE MARROW TOXICITY; CANCER INCIDENCE; CLINICAL ARTICLE; FEMALE; FOLLOW UP; GERMANY; HUMAN; MALE; META ANALYSIS; MULTIPLE CYCLE TREATMENT; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; RETROSPECTIVE STUDY;

EID: 84858662103     PISSN: 17562856     EISSN: 17562864     Source Type: Journal    
DOI: 10.1177/1756285611433318     Document Type: Article

References (9)

1. Cotte S. von Ahsen N. Kruse N. Huber B. Winkelmann A. Zettl U.K. et al. (2009) ABC-transporter gene-polymorphisms are potential pharmacogenetic markers for mitoxantrone response in multiple sclerosis. Brain 132: 2517–2530.
2. Ellis R. Boggild M. (2009) Therapy-related acute leukaemia with Mitoxantrone: what is the risk and can we minimise it? Mult Scler 15: 505–508.
3. Flachenecker P. Stuke K. Elias W. Freidel M. Haas J. Pitschnau-Michel D. et al. (2008) Multiple sclerosis registry in Germany results of the extension phase 2005 / 2006. Dtsch Arztebl Int 105: 113–119.
4. Ghalie R.G. Mauch E. Edan G. Hartung H.P. Gonsette R.E. Eisenmann S. et al. (2002) A study of therapy-related acute leukaemia after mitoxantrone therapy for multiple sclerosis. Mult Scler 8: 441–445.
5. Hartung H.P. Gonsette R. König N. Kwiecinski H. Guseo A. Morrissey S.P. et al. (2002) Mitoxantrone in progressive multiple sclerosis: a placebocontrolled, double-blind, randomised, multicentre trial. Lancet 360: 2018–2025.
6. Le Page E. Leray E. Edan G. (2011) Long-term safety profile of mitoxantrone in a French cohort of 802 multiple sclerosis patients: a 5-year prospective study. Mult Scler. 17: 867–875.
7. Marriott J.J. Miyasaki J.M. Gronseth G. O'connor P.W. (2010) Evidence Report: The efficacy and safety of mitoxantrone (Novantrone) in the treatment of multiple sclerosis: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 74: 1463–1470.
8. Pascual A.M. Téllez N. Bosca I. Mallada J. Belenguer A. Abellan I. et al. (2009) Revision of the risk of secondary leukaemia after mitoxantrone in multiple sclerosis populations is required. Mult Scler. 15: 1303–1310.
9. Rivera V. Weinstock-Guttman B. Beagan J. Mallada J. Belenguer A. Abellan I. (2009) Final results from Registry to Evaluate Novantrone Effects in Worsening Multiple sclerosis study (RENEW). Mult Scler 15: S254.